JP6134139B2 - ヘルパーｔ細胞の活性化方法 - Google Patents

ヘルパーｔ細胞の活性化方法 Download PDF

Info

Publication number
JP6134139B2
JP6134139B2 JP2012537718A JP2012537718A JP6134139B2 JP 6134139 B2 JP6134139 B2 JP 6134139B2 JP 2012537718 A JP2012537718 A JP 2012537718A JP 2012537718 A JP2012537718 A JP 2012537718A JP 6134139 B2 JP6134139 B2 JP 6134139B2
Authority
JP
Japan
Prior art keywords
hla
molecule
drb1
peptide
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012537718A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2012046730A1 (ja
Inventor
治夫 杉山
治夫 杉山
真司 十河
真司 十河
佐藤　政芳
政芳 佐藤
竜生 北本
竜生 北本
義博 後藤
義博 後藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
International Institute of Cancer Immunology Inc
Original Assignee
Otsuka Pharmaceutical Co Ltd
International Institute of Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd, International Institute of Cancer Immunology Inc filed Critical Otsuka Pharmaceutical Co Ltd
Publication of JPWO2012046730A1 publication Critical patent/JPWO2012046730A1/ja
Application granted granted Critical
Publication of JP6134139B2 publication Critical patent/JP6134139B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012537718A 2010-10-05 2011-10-04 ヘルパーｔ細胞の活性化方法 Active JP6134139B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010225806 2010-10-05
JP2010225806 2010-10-05
PCT/JP2011/072874 WO2012046730A1 (ja) 2010-10-05 2011-10-04 ヘルパーｔ細胞の活性化方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016109398A Division JP6298101B2 (ja) 2010-10-05 2016-05-31 ヘルパーｔ細胞の活性化方法

Publications (2)

Publication Number Publication Date
JPWO2012046730A1 JPWO2012046730A1 (ja) 2014-02-24
JP6134139B2 true JP6134139B2 (ja) 2017-05-24

Family

ID=45927725

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012537718A Active JP6134139B2 (ja) 2010-10-05 2011-10-04 ヘルパーｔ細胞の活性化方法
JP2016109398A Active JP6298101B2 (ja) 2010-10-05 2016-05-31 ヘルパーｔ細胞の活性化方法
JP2017237964A Pending JP2018093870A (ja) 2010-10-05 2017-12-12 ヘルパーｔ細胞の活性化方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016109398A Active JP6298101B2 (ja) 2010-10-05 2016-05-31 ヘルパーｔ細胞の活性化方法
JP2017237964A Pending JP2018093870A (ja) 2010-10-05 2017-12-12 ヘルパーｔ細胞の活性化方法

Country Status (21)

Country Link
US (2) US10654892B2 (OSRAM)
EP (1) EP2626418B8 (OSRAM)
JP (3) JP6134139B2 (OSRAM)
KR (3) KR102171794B1 (OSRAM)
CN (2) CN105802910A (OSRAM)
AR (1) AR083295A1 (OSRAM)
AU (1) AU2011313327B2 (OSRAM)
BR (1) BR112013008230A2 (OSRAM)
CA (1) CA2813557C (OSRAM)
CO (1) CO6710946A2 (OSRAM)
EA (1) EA037547B1 (OSRAM)
ES (1) ES2849187T3 (OSRAM)
IL (2) IL225536B (OSRAM)
MX (2) MX361299B (OSRAM)
MY (1) MY170306A (OSRAM)
NZ (2) NZ609460A (OSRAM)
PH (1) PH12013500654A1 (OSRAM)
SG (3) SG10202108581TA (OSRAM)
TW (2) TWI608099B (OSRAM)
WO (1) WO2012046730A1 (OSRAM)
ZA (1) ZA201303056B (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2071028T3 (pl) 2003-11-05 2012-06-29 Int Inst Cancer Immunology Inc Pochodzący z WT1 peptyd antygenowy wiążący się z HLA-DR
CA2626238C (en) 2005-10-17 2015-10-06 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
EP2010209B1 (en) 2006-04-10 2016-06-15 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
MY158219A (en) 2007-02-27 2016-09-15 Int Inst Cancer Immunology Inc Method for activation of helper t cell and composition for use in the method
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
MX361299B (es) * 2010-10-05 2018-11-30 Otsuka Pharmaceutical Co Ltd Star Metodo para activar celulas auxiliares.
EP3520810A3 (en) 2012-01-13 2019-11-06 Memorial Sloan-Kettering Cancer Center Immunogenic wt1 peptides and use thereof
JP6535463B2 (ja) * 2012-09-12 2019-06-26 株式会社癌免疫研究所 抗原特異的ヘルパーｔ細胞レセプター遺伝子
BR112015013697A2 (pt) * 2012-12-17 2017-11-14 Univ Osaka método para ativar célula t auxiliar
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
PL2945647T3 (pl) 2013-01-15 2021-03-08 Memorial Sloan Kettering Cancer Center Immunogenne peptydy wt-1 i sposoby ich zastosowania
EP3461493A1 (en) 2013-03-29 2019-04-03 Sumitomo Dainippon Pharma Co., Ltd. Wt1 antigen peptide conjugate vaccine
EP3112378B1 (en) * 2014-02-26 2020-06-24 Tella, Inc. Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
CA2974066C (en) 2014-12-25 2025-05-06 International Institute Of Cancer Immunology, Inc. METHOD FOR MODIFYING A T LYMPHOCYTE POPULATION
CN106565836B (zh) * 2015-10-10 2020-08-18 中国科学院广州生物医药与健康研究院 高亲和力的可溶性pdl-1分子
JP6994201B2 (ja) 2016-11-09 2022-02-21 国立大学法人大阪大学 Ｔ細胞集団の改変方法
EP3549957A4 (en) * 2016-11-30 2020-08-05 Sumitomo Dainippon Pharma Co., Ltd. AUXILIARY PEPTIDE WT1, AND COMBINATION OF DUDIT PEPTIDE AND CONJUGATE PEPTIDE ANTIGENIC FOR CANCER
WO2019131722A1 (ja) * 2017-12-27 2019-07-04 大日本住友製薬株式会社 Ｗｔ１由来ペプチドのコンジュゲート体およびこれを含む組成物
JP6857930B2 (ja) * 2018-02-15 2021-04-14 国立大学法人旭川医科大学 がん抗原ペプチド
CA3109496A1 (en) * 2018-08-22 2020-02-27 Fred Hutchinson Cancer Research Center Immunotherapy targeting kras or her2 antigens

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005045027A1 (ja) * 2003-11-05 2005-05-19 International Institute Of Cancer Immunology, Inc. Ｗｔ１由来のｈｌａ−ｄｒ結合性抗原ペプチド
WO2008105462A1 (ja) * 2007-02-27 2008-09-04 International Institute Of Cancer Immunology, Inc. ヘルパーｔ細胞の活性化方法およびそのための組成物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726288A (en) 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
CA2337743C (en) 1998-07-31 2015-07-07 Yoshihiro Oka Tumor antigen based on products of the tumor suppressor gene wt1
BR9914116A (pt) 1998-09-30 2002-01-15 Corixa Corp Composições e métodos para imunoterapia especìfica de wt1
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
AU2001247220A1 (en) 2000-02-22 2001-09-03 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
CN1281625C (zh) 2001-03-22 2006-10-25 株式会社癌免疫研究所 经修饰的wt1肽
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
CN1320923C (zh) 2001-06-29 2007-06-13 中外制药株式会社 含有基于癌抑制基因wt1的产物的癌抗原和阳离子脂质体的癌疫苗
US8735357B2 (en) 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
EP1447092A4 (en) 2001-09-28 2007-07-11 Haruo Sugiyama METHODS OF INDUCING ANTIGEN-SPECIFIC T CELLS
JP4365784B2 (ja) 2002-06-12 2009-11-18 株式会社癌免疫研究所 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
ES2538486T3 (es) 2002-09-12 2015-06-22 International Institute Of Cancer Immunology, Inc. Preparación de péptidos antigénicos contra el cáncer
EP1548028B1 (en) 2002-09-20 2009-09-09 International Institute of Cancer Immunology, Inc. Substituted type peptides of wt1
CA2513701C (en) 2003-01-15 2013-06-18 Haruo Sugiyama Dimerized peptide
EP2343083B1 (en) 2003-06-27 2014-01-15 International Institute of Cancer Immunology, Inc. Method of diagnosing cancer comprising the measurement of WT1-specific CTL precursor cells
DK2186896T3 (en) 2004-03-31 2015-12-21 Int Inst Cancer Immunology Inc Cancer antigen peptides derived from WT1
US7608769B2 (en) * 2004-05-12 2009-10-27 First Act, Inc. Packaged drum set
JP4719876B2 (ja) 2005-04-04 2011-07-06 国立大学法人愛媛大学 Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド
CA2626238C (en) 2005-10-17 2015-10-06 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
WO2007063903A1 (ja) 2005-11-30 2007-06-07 International Institute Of Cancer Immunology, Inc. 新規ペプチド化合物
US7420880B2 (en) 2005-12-29 2008-09-02 Timex Group B.V. Multimode electronic device with calibrating/setting mechanism
CN102250211A (zh) 2006-02-22 2011-11-23 株式会社癌免疫研究所 Hla-a*3303限制性wt1肽和包含此肽的药物组合物
EP2010209B1 (en) 2006-04-10 2016-06-15 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
SI2341142T1 (sl) * 2006-12-28 2015-03-31 International Institute Of Cancer Immunology, Inc. HLA-A*1101-omejen WT1 peptid in farmacevtski sestavek, ki ga vsebuje
EP2116596A4 (en) 2007-03-05 2010-04-07 Int Inst Cancer Immunology Inc L-CELL RECEPTOR GENE SPECIFIC TO A CANCER ANTIGEN, PEPTIDE CODED BY THE GENE AND THEIR USE
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
MX361299B (es) * 2010-10-05 2018-11-30 Otsuka Pharmaceutical Co Ltd Star Metodo para activar celulas auxiliares.
BR112015013697A2 (pt) 2012-12-17 2017-11-14 Univ Osaka método para ativar célula t auxiliar

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005045027A1 (ja) * 2003-11-05 2005-05-19 International Institute Of Cancer Immunology, Inc. Ｗｔ１由来のｈｌａ−ｄｒ結合性抗原ペプチド
WO2008105462A1 (ja) * 2007-02-27 2008-09-04 International Institute Of Cancer Immunology, Inc. ヘルパーｔ細胞の活性化方法およびそのための組成物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6015039093; Ｃｌｉｎｉｃａｌ Ｃａｎｃｅｒ Ｒｅｓｅａｒｃｈ ｖｏｌ． １３， ｎｏ． １５, 2007, ｐａｇｅｓ ４５４７ - ４５５５ *
JPN6015039095; ＨＥＭＡＴＯＬＯＧＹ ＪＯＵＲＮＡＬ ｖｏｌ． ４， ｎｏ． １, 2003, ｐａｇｅｓ ５７ - ６６ *
JPN6015039096; Ｃａｎｃｅｒ Ｒｅｓｅａｒｃｈ ｖｏｌ． ６８, 2008, ｐａｇｅｓ ６３５０ - ６３５９ *
JPN6015039098; ＭＩＣＲＯＢＩＯＬ． ＩＭＭＵＮＯＬ． ｖｏｌ． ５２, 2008, ｐａｇｅｓ ５９１ - ６００ *

Also Published As

Publication number Publication date
JPWO2012046730A1 (ja) 2014-02-24
KR102171794B1 (ko) 2020-10-29
CN103298928A (zh) 2013-09-11
IL245440A0 (en) 2016-06-30
CO6710946A2 (es) 2013-07-15
EP2626418B1 (en) 2020-12-09
PH12013500654A1 (en) 2013-05-06
SG10201508252PA (en) 2015-11-27
MX2018008436A (es) 2021-12-08
IL225536A0 (en) 2013-06-27
MX361299B (es) 2018-11-30
TWI608099B (zh) 2017-12-11
TW201623616A (zh) 2016-07-01
US10654892B2 (en) 2020-05-19
NZ609460A (en) 2015-07-31
CN103298928B (zh) 2016-04-20
US20130266958A1 (en) 2013-10-10
US12415833B2 (en) 2025-09-16
IL225536B (en) 2019-03-31
JP6298101B2 (ja) 2018-03-20
KR20140009168A (ko) 2014-01-22
AU2011313327B2 (en) 2015-10-22
BR112013008230A2 (pt) 2016-06-14
AU2011313327A1 (en) 2013-05-02
EP2626418A4 (en) 2014-02-19
JP2017006120A (ja) 2017-01-12
ES2849187T3 (es) 2021-08-16
SG10202108581TA (en) 2021-09-29
KR102079480B1 (ko) 2020-02-19
ZA201303056B (en) 2013-12-23
CA2813557A1 (en) 2012-04-12
EA201390509A1 (ru) 2013-08-30
SG189287A1 (en) 2013-05-31
TW201217525A (en) 2012-05-01
EA037547B1 (ru) 2021-04-12
EP2626418B8 (en) 2021-03-24
CA2813557C (en) 2021-05-04
KR20190034359A (ko) 2019-04-01
EP2626418A1 (en) 2013-08-14
AR083295A1 (es) 2013-02-13
NZ703560A (en) 2016-11-25
MY170306A (en) 2019-07-17
MX2013003884A (es) 2013-07-05
US20200354405A1 (en) 2020-11-12
KR20200018738A (ko) 2020-02-19
WO2012046730A1 (ja) 2012-04-12
CN105802910A (zh) 2016-07-27
JP2018093870A (ja) 2018-06-21

Similar Documents

Publication Publication Date Title
JP6298101B2 (ja) ヘルパーｔ細胞の活性化方法
JP6530192B2 (ja) ヘルパーｔ細胞の活性化方法
HK1188465B (en) Method for activating helper t cell
HK1188465A (en) Method for activating helper t cell

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151119

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170227

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170421

R150 Certificate of patent or registration of utility model

Ref document number: 6134139

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250